Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Tenax Therapeutics (TENX)

Tenax Therapeutics (TENX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Tenax Therapeutics: Q3 Earnings Snapshot AP - Tue Nov 14, 2023

Tenax Therapeutics: Q3 Earnings Snapshot

TENX : 3.56 (+1.71%)
Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) Spotlight Growth - Thu Feb 2, 2023

Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and

TENX : 3.56 (+1.71%)
Wall Street - NYSE Full View
Stocks Set To Open Higher As Dovish Powell Comments Boost Sentiment, ECB Decision In Focus Barchart - Thu Feb 2, 2023

March S&P 500 futures (ESH23) are trending up +0.47% this morning after three major U.S. benchmark indices staged a rebound on Wednesday after the Federal Reserve announced a further slowdown in the pace...

ESH23 : 3,957.05s (-0.09%)
META : 493.50 (-0.52%)
AAPL : 169.02 (+1.27%)
GOOG : 161.10 (+0.74%)
AMZN : 176.59 (-1.64%)
MRK : 127.00 (+0.09%)
COP : 129.28 (-0.43%)
F : 12.95 (+0.08%)
SHEL.LN : 2,907.000 (+0.41%)
TENX : 3.56 (+1.71%)
ALGN : 313.78 (+0.61%)
ELF : 176.98 (-0.01%)
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH) Business Wire - Wed May 25, 2022

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.56 (+1.71%)
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension Business Wire - Mon May 23, 2022

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.56 (+1.71%)
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules Business Wire - Wed May 18, 2022

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.56 (+1.71%)
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update Business Wire - Thu Mar 31, 2022

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.56 (+1.71%)
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions Business Wire - Wed Mar 30, 2022

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.56 (+1.71%)
Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors Globe Newswire - Mon Jan 31, 2022

MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...

TENX : 3.56 (+1.71%)
Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102) Globe Newswire - Wed Jan 12, 2022

Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible...

TENX : 3.56 (+1.71%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip Barchart - 31 minutes ago
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot